{"id":"ipv-al","safety":{"commonSideEffects":[{"rate":null,"effect":"Local injection site reactions (pain, redness, swelling)"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Irritability or fussiness"}]},"_chembl":{"chemblId":"CHEMBL3961932","moleculeType":"Small molecule","molecularWeight":"423.48"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IPV-Al contains chemically inactivated (killed) poliovirus particles of types 1, 2, and 3, which are administered intramuscularly to induce humoral and cellular immune responses. This vaccination prevents infection by poliovirus and the development of poliomyelitis. The vaccine is adsorbed onto aluminum hydroxide adjuvant to enhance immunogenicity.","oneSentence":"IPV-Al is an inactivated poliovirus vaccine that stimulates the immune system to produce antibodies against all three poliovirus serotypes.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:50:10.398Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Poliomyelitis prevention in infants, children, and adults"}]},"trialDetails":[{"nctId":"NCT07226401","phase":"NA","title":"Virtual Village for Young Parents","status":"RECRUITING","sponsor":"RTI International","startDate":"2025-11-11","conditions":"Gender-based Violence, Intimate Partner Violence","enrollment":80},{"nctId":"NCT06576193","phase":"NA","title":"Empowering Young Parents: Building Healthy Relationships Study","status":"RECRUITING","sponsor":"RTI International","startDate":"2024-10-16","conditions":"Gender-based Violence, Intimate Partner Violence","enrollment":600},{"nctId":"NCT05674591","phase":"NA","title":"Cognitive Processing Therapy in Syrian Women Exposed to IPV","status":"COMPLETED","sponsor":"British University In Egypt","startDate":"2021-01-05","conditions":"Depression, Anxiety, PTSD","enrollment":30},{"nctId":"NCT04448132","phase":"PHASE4","title":"Evaluation of Persistence of Immunity in 4-year-old Children Previously Immunised With IPV-Al AJV (Picovax®)","status":"COMPLETED","sponsor":"AJ Vaccines A/S","startDate":"2020-11-20","conditions":"Poliomyelitis","enrollment":163},{"nctId":"NCT03032419","phase":"PHASE3","title":"Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given at 6, 10, 14 Weeks and 9 Months","status":"COMPLETED","sponsor":"Statens Serum Institut","startDate":"2017-02-06","conditions":"Poliomyelitis","enrollment":1002},{"nctId":"NCT03025750","phase":"PHASE3","title":"Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine in 2, 4, 6 Months of Age","status":"COMPLETED","sponsor":"Statens Serum Institut","startDate":"2017-01-19","conditions":"Poliomyelitis","enrollment":800},{"nctId":"NCT02280447","phase":"PHASE1, PHASE2","title":"3 Adjuvated Reduced Dose IPV-Al SSI Vaccines and Non-adjuvated Full Dose IPV SSI, as Booster Vaccination to Adolescents","status":"COMPLETED","sponsor":"Statens Serum Institut","startDate":"2014-11-13","conditions":"Immunization, Booster","enrollment":240},{"nctId":"NCT02347423","phase":"PHASE2","title":"3 Adjuvated Reduced Dose IPV-Al SSI and Non-adjuvated Full Dose IPV SSI Given as Primary Vaccinations to Infants","status":"COMPLETED","sponsor":"Statens Serum Institut","startDate":"2015-02","conditions":"Poliomyelitis","enrollment":824},{"nctId":"NCT03671616","phase":"PHASE3","title":"Immunogenicity and Safety of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given as a Booster at Age 15-18 Months","status":"COMPLETED","sponsor":"Statens Serum Institut","startDate":"2018-05-15","conditions":"Poliomyelitis","enrollment":666}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Picovax®","IPV-Al AJV"],"phase":"marketed","status":"active","brandName":"IPV-Al","genericName":"IPV-Al","companyName":"AJ Vaccines A/S","companyId":"aj-vaccines-a-s","modality":"Biologic","firstApprovalDate":"","aiSummary":"IPV-Al is an inactivated poliovirus vaccine that stimulates the immune system to produce antibodies against all three poliovirus serotypes. Used for Poliomyelitis prevention in infants, children, and adults.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}